52 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Spherix, Inc. SPEX shares surged 66.5% to $2.73 during Monday's pre-market session.
• Cocrystal Pharma, Inc. COCP stock rose 50.0% to $1.77.
• Enzo Biochem, Inc. ENZ shares increased by 36.5% to $4.60.
• China SXT Pharmaceuticals, Inc. SXTC stock increased by 25.6% to $1.08.
• OPKO Health, Inc. OPK shares rose 24.1% to $2.88.
• Inovio Pharmaceuticals, Inc. INO shares surged 23.5% to $17.40. The most recent rating by PiperJaffray, on January 03, is at Overweight, with a price target of $8.00.
• Vaxart, Inc. VXRT shares moved upwards by 22.7% to $3.14.
• Trinity Biotech, Inc. TRIB stock surged 14.3% to $1.60.
• Kala Pharmaceuticals, Inc. KALA shares increased by 12.3% to $7.05. According to the most recent rating by Bank of America, on December 17, the current rating is at Neutral.
• Ritter Pharmaceuticals, Inc. RTTR shares surged 8.4% to $0.44.
• Co-Diagnostics, Inc. CODX stock moved upwards by 8.0% to $13.92. According to the most recent rating by Maxim Group, on March 03, the current rating is at Hold.
• T2 Biosystems, Inc. TTOO shares moved upwards by 7.6% to $0.60.
• Spectrum Pharmaceuticals, Inc. SPPI stock surged 7.2% to $2.99. The most recent rating by B. Riley FBR, on March 02, is at Buy, with a price target of $8.00.
• Tonix Pharmaceuticals, Inc. TNXP shares moved upwards by 6.8% to $1.10.
• Compugen, Inc. CGEN stock rose 6.3% to $9.95. The most recent rating by Cantor Fitzgerald, on February 21, is at Overweight, with a price target of $13.00.
• Novavax, Inc. NVAX shares rose 5.8% to $13.20. The most recent rating by B. Riley FBR, on February 28, is at Buy, with a price target of $16.00.

Losers

• NewLink Genetics, Inc. NLNK stock fell 19.6% to $1.11 during Monday's pre-market session.
• Clovis Oncology, Inc. CLVS stock fell 16.5% to $6.56. The most recent rating by B of A Securities, on January 23, is at Neutral, with a price target of $10.00.
• Tilray, Inc. TLRY stock decreased by 15.7% to $8.45. According to the most recent rating by Eight Capital, on March 03, the current rating is at Neutral.
• Canopy Growth, Inc. CGC stock plummeted 14.7% to $13.03. The most recent rating by Stifel Nicolaus, on February 18, is at Buy, with a price target of $35.00.
• Tocagen, Inc. TOCA stock decreased by 13.2% to $2.50.
• Bionano Genomics, Inc. BNGO shares declined 12.4% to $0.67.
• Aurora Cannabis, Inc. ACB stock declined 11.1% to $1.04. The most recent rating by Needham, on February 25, is at Hold, with a price target of $1.50.
• Amarin Corp, Inc. AMRN shares decreased by 8.7% to $13.62. The most recent rating by Cowen & Co., on March 02, is at Outperform, with a price target of $23.00.
• Titan Pharmaceuticals, Inc. TTNP stock fell 8.5% to $0.28.
• Teva Pharmaceutical Indus, Inc. TEVA shares decreased by 8.4% to $9.43. The most recent rating by Wells Fargo, on March 05, is at Equal-Weight, with a price target of $12.00.
• Verastem, Inc. VSTM shares fell 8.3% to $3.10. The most recent rating by Cantor Fitzgerald, on March 03, is at Overweight, with a price target of $6.00.
• Enlivex Therapeutics, Inc. ENLV stock plummeted 7.8% to $5.30. The most recent rating by H.C. Wainwright, on January 09, is at Buy, with a price target of $20.00.
• Aphria, Inc. APHA shares decreased by 7.5% to $2.91. According to the most recent rating by CiBC, on January 15, the current rating is at Neutral.
• Sorrento Therapeutics, Inc. SRNE shares plummeted 7.2% to $2.05.
• AbbVie, Inc. ABBV stock declined 7.1% to $82.65. The most recent rating by Barclays, on February 27, is at Equal-Weight, with a price target of $97.00.
• Arrowhead Pharmaceuticals, Inc. ARWR shares declined 7.0% to $31.06. The most recent rating by Cantor Fitzgerald, on February 06, is at Neutral, with a price target of $55.00.
• Bristol-Myers Squibb, Inc. BMY stock plummeted 6.3% to $56.50. The most recent rating by Barclays, on February 27, is at Equal-Weight, with a price target of $69.00.
• Trillium Therapeutics, Inc. TRIL shares plummeted 6.1% to $6.78.
• CVS Health, Inc. CVS stock plummeted 6.1% to $60.25. The most recent rating by Deutsche Bank, on February 18, is at Buy, with a price target of $109.00.
• UnitedHealth Group, Inc. UNH shares decreased by 6.0% to $267.00. The most recent rating by Deutsche Bank, on February 18, is at Hold, with a price target of $362.00.
• Allied Healthcare Prods, Inc. AHPI stock declined 6.0% to $17.01.
• Abbott Laboratories, Inc. ABT shares decreased by 5.9% to $76.95. The most recent rating by Credit Suisse, on March 06, is at Outperform, with a price target of $94.00.
• Editas Medicine, Inc. EDIT stock declined 5.8% to $22.57. The most recent rating by Raymond James, on February 27, is at Outperform, with a price target of $41.00.
• Advaxis, Inc. ADXS stock declined 5.8% to $0.75.
• ADMA Biologics, Inc. ADMA stock plummeted 5.7% to $2.82.
• Merck & Co, Inc. MRK shares decreased by 5.5% to $77.70. The most recent rating by UBS, on February 06, is at Buy, with a price target of $96.00.
• Beyond Air, Inc. XAIR stock plummeted 5.5% to $7.00.
• Sanofi, Inc. SNY stock declined 5.3% to $45.89. The most recent rating by Argus Research, on February 19, is at Buy, with a price target of $56.00.
• Royal Philips, Inc. PHG stock plummeted 5.2% to $39.88. The most recent rating by Bank of America, on January 13, is at Buy, with a price target of $51.00.
• Digirad, Inc. DRAD shares fell 5.0% to $6.50.
• Pfizer, Inc. PFE shares fell 4.6% to $33.41. The most recent rating by Barclays, on February 27, is at Equal-Weight, with a price target of $36.00.
• Novo Nordisk, Inc. NVO stock plummeted 4.3% to $59.87. The most recent rating by KeyBanc, on February 19, is at Overweight, with a price target of $18.00.
• Johnson & Johnson, Inc. JNJ stock plummeted 4.2% to $136.20. The most recent rating by Credit Suisse, on March 06, is at Outperform, with a price target of $159.00.
• Medtronic, Inc. MDT stock fell 4.1% to $94.99. The most recent rating by Credit Suisse, on March 06, is at Outperform, with a price target of $121.00.
• KemPharm, Inc. KMPH stock decreased by 3.6% to $0.27.
• Grifols, Inc. GRFS stock fell 3.3% to $21.34.